Clear All
11564 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
71288-0158-96 71288-0158 Busulfan Busulfan 6.0 mg/mL Chemotherapy Alkylating Agent Alkylsulfonate Intravenous Oct 23, 2020 In Use
59148-0047-91 59148-0047 Busulfan Busulfex 6.0 mg/mL Chemotherapy Alkylating Agent Alkylsulfonate Intravenous Feb 13, 2015 Jan 31, 2021 No Longer Used
55150-0395-08 55150-0395 Busulfan Busulfan 6.0 mg/mL Chemotherapy Alkylating Agent Alkylsulfonate Intravenous Jun 25, 2024 In Use
00517-0920-08 00517-0920 Busulfan Busulfan 6.0 mg/mL Chemotherapy Alkylating Agent Alkylsulfonate Intravenous Apr 1, 2017 In Use
70860-0216-10 70860-0216 Busulfan Busulfan 6.0 mg/mL Chemotherapy Alkylating Agent Alkylsulfonate Intravenous Feb 10, 2019 Jul 31, 2021 No Longer Used
25021-0241-10 25021-0241 Busulfan Busulfan 6.0 mg/mL Chemotherapy Alkylating Agent Alkylsulfonate Intravenous May 15, 2017 In Use
76388-0713-25 76388-0713 Busulfan Myleran 2.0 mg/1 Chemotherapy Alkylating Agent Alkylsulfonate Oral Mar 21, 1985 Jun 30, 2023 No Longer Used
51817-0170-01 51817-0170 Busulfan Busulfan 6.0 mg/mL Chemotherapy Alkylating Agent Alkylsulfonate Intravenous May 19, 2017 In Use
76189-0113-18 76189-0113 Brigatinib Alunbrig 30.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ALK/ROS1/ EGFR Oral Apr 28, 2017 Dec 12, 2020 No Longer Used
76189-0113-21 76189-0113 Brigatinib Alunbrig 30.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ALK/ROS1/ EGFR Oral Apr 28, 2017 Dec 12, 2020 No Longer Used
71287-0219-02 71287-0219 brexucabtagene autoleucel TECARTUS 2000000.0 1/68mL Immunotherapy CAR-T CD19 Intravenous Jul 24, 2020 In Use
71287-0220-02 71287-0220 brexucabtagene autoleucel TECARTUS 1000000.0 1/68mL Immunotherapy CAR-T CD19 Intravenous Oct 1, 2021 In Use
51144-0050-01 51144-0050 Brentuximab vedotin Adcetris 50.0 mg/10.5mL Immunotherapy Drug Antibody Conjugate CD30 Intravenous Aug 25, 2011 In Use
00069-1014-15 00069-1014 Bosutinib BOSULIF 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Jan 2, 2024 In Use
00069-0504-30 00069-0504 Bosutinib BOSULIF 50.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Jan 2, 2024 In Use
63539-0117-01 63539-0117 Bosutinib monohydrate, Bosutinib Bosulif 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sep 4, 2012 In Use
00069-0135-01 00069-0135 Bosutinib monohydrate, Bosutinib Bosulif 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sep 4, 2012 In Use
00069-0193-01 00069-0193 Bosutinib monohydrate, Bosutinib BOSULIF 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Dec 18, 2017 In Use
00069-0136-01 00069-0136 Bosutinib monohydrate, Bosutinib Bosulif 500.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sep 4, 2012 In Use
00409-1704-01 00409-1704 BORTEZOMIB BORTEZOMIB 1.0 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous May 16, 2022 In Use
72266-0244-01 72266-0244 Bortezomib Bortezomib 2.5 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous Aug 23, 2022 Jun 30, 2024 No Longer Used
63759-3032-01 63759-3032 Bortezomib Bortezomib 3.5 mg/1.4mL Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous Sep 25, 2024 In Use
70511-0161-05 70511-0161 Bortezomib Bortezomib 1.0 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous Aug 11, 2022 In Use
60505-6050-04 60505-6050 Bortezomib BORTEZOMIB 3.5 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous May 2, 2022 Dec 31, 2028 In Use
83703-0532-01 83703-0532 Bortezomib BORTEZOMIB 3.5 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous May 2, 2022 In Use

Found 11564 results — Export these results